Loading...
XJPX4151
Market cap7.74bUSD
Dec 23, Last price  
2,384.50JPY
1D
0.38%
1Q
-23.08%
Jan 2017
47.56%
Name

Kyowa Kirin Co Ltd

Chart & Performance

D1W1MN
XJPX:4151 chart
P/E
14.99
P/S
2.75
EPS
159.08
Div Yield, %
2.39%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
5.00%
Revenues
442.23b
+11.01%
358,963,000,000353,440,000,000354,274,000,000392,120,000,000460,183,000,0000413,738,000,000343,722,000,000333,158,000,000340,611,000,000333,446,000,000364,316,000,000343,019,000,000353,380,000,000346,531,000,000305,820,000,000318,352,000,000352,246,000,000398,371,000,000442,233,000,000
Net income
81.19b
+51.55%
17,932,000,00016,273,000,00012,694,000,00023,477,000,00011,726,000,000022,197,000,00025,608,000,00024,199,000,00030,078,000,00015,898,000,00029,774,000,00018,669,000,00042,899,000,00054,414,000,00037,674,000,00047,027,000,00052,347,000,00053,573,000,00081,188,000,000
CFO
115.55b
+137.41%
34,264,000,00030,104,000,00014,303,000,00023,381,000,00030,714,000,00041,069,000,00064,189,000,00040,634,000,00059,134,000,00056,884,000,00019,377,000,00066,526,000,00065,752,000,00064,903,000,00056,181,000,00053,657,000,00039,501,000,00086,546,000,00048,672,000,000115,551,000,000
Dividend
Dec 27, 202429 JPY/sh
Earnings
Feb 05, 2025

Profile

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
URL
https://www.kyowakirin.co.jp/
IPO date
Aug 22, 1949
Employees
5,982
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
442,233,000
11.01%
398,371,000
13.09%
352,246,000
10.65%
Cost of revenue
346,391,000
363,329,000
329,694,000
Unusual Expense (Income)
NOPBT
95,842,000
35,042,000
22,552,000
NOPBT Margin
21.67%
8.80%
6.40%
Operating Taxes
16,058,000
14,000,000
7,703,000
Tax Rate
16.75%
39.95%
34.16%
NOPAT
79,784,000
21,042,000
14,849,000
Net income
81,188,000
51.55%
53,573,000
2.34%
52,347,000
11.31%
Dividends
(29,027,000)
(25,258,000)
(24,176,000)
Dividend yield
2.28%
1.56%
1.43%
Proceeds from repurchase of equity
(10,000)
(11,000)
(23,000)
BB yield
0.00%
0.00%
0.00%
Debt
Debt current
5,729,000
5,943,000
Long-term debt
31,827,000
34,451,000
16,594,000
Deferred revenue
(16,902,000)
Other long-term liabilities
40,143,000
66,826,000
75,195,000
Net debt
(418,910,000)
(335,545,000)
(357,711,000)
Cash flow
Cash from operating activities
115,551,000
48,672,000
86,546,000
CAPEX
(17,213,000)
(28,666,000)
(19,766,000)
Cash from investing activities
(20,382,000)
(17,185,000)
(11,362,000)
Cash from financing activities
(32,535,000)
(29,032,000)
(28,446,000)
FCF
91,999,000
(9,251,000)
12,883,000
Balance
Cash
405,006,000
339,720,000
336,518,000
Long term investments
45,731,000
36,005,000
43,730,000
Excess cash
428,625,350
355,806,450
362,635,700
Stockholders' equity
374,620,000
312,587,000
282,273,000
Invested Capital
517,657,000
521,212,000
522,601,000
ROIC
15.36%
4.03%
3.00%
ROCE
10.74%
4.20%
2.80%
EV
Common stock shares outstanding
537,635
537,570
537,514
Price
2,370.00
-21.52%
3,020.00
-3.67%
3,135.00
11.41%
Market cap
1,274,193,820
-21.51%
1,623,462,176
-3.66%
1,685,106,923
11.41%
EV
855,283,820
1,298,935,176
1,333,300,923
EBITDA
116,938,000
53,518,000
42,050,000
EV/EBITDA
7.31
24.27
31.71
Interest
190,000
1,088,000
1,117,000
Interest/NOPBT
0.20%
3.10%
4.95%